Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance

2025 ICD-10-CM code R87.821

Positive vaginal low-risk human papillomavirus (HPV) DNA test.

Follow current ICD-10-CM coding guidelines and official documentation.Use additional codes to specify other conditions or findings.

Modifiers may be applicable to procedural codes associated with the diagnosis.For example, modifiers indicating the technical component or professional component may be used if those services are provided separately.

Medical necessity for HPV testing is established based on factors like age, sexual activity, prior abnormal Pap smears, immunosuppression, and other risk factors for cervical cancer.Routine screening guidelines vary, and payer policies may further define what constitutes medically necessary testing.

The clinical responsibility for a positive vaginal low-risk HPV DNA test result lies with the healthcare professional interpreting the results and determining the appropriate management plan.This may involve counseling, further testing (such as repeat testing or colposcopy), and ongoing monitoring.The physician's role includes patient education, risk assessment, and providing appropriate management based on the patient's individual health situation.

IMPORTANT May be used in conjunction with B97.7 (HPV as the cause of diseases classified elsewhere) to specify HPV as the etiology.Consider also R87.820 (cervical low-risk HPV DNA test positive) if the specimen was cervical.ICD-9-CM codes 795.19 (other abnormal Papanicolaou smear of vagina and vaginal HPV) may be relevant for comparison purposes.

In simple words: This code means a test came back positive for a low-risk type of the human papillomavirus (HPV) in a sample from the vagina. HPV is a common virus, and some types are more likely to cause problems than others. This result needs more examination to see if any treatment is needed.

This code signifies a positive result from a DNA test for low-risk human papillomavirus (HPV) in a vaginal specimen.The test specifically identifies the presence of low-risk HPV types, which are generally associated with less severe health consequences compared to high-risk HPV types.This finding requires further clinical evaluation to determine the appropriate management strategy, depending on patient-specific factors and the presence of other clinical findings.

Example 1: A 25-year-old female presents for a routine gynecological exam.A vaginal Pap smear and HPV DNA test are performed.The Pap smear is normal, but the HPV DNA test is positive for low-risk HPV types. The physician discusses the results, the low risk associated with these types, and the need for routine follow-up., A 30-year-old female with a history of abnormal Pap smears undergoes a colposcopy. Biopsies are taken, and HPV DNA testing is performed on the vaginal sample. The results show the presence of low-risk HPV types.The physician reviews the results with the patient and determines the appropriate follow-up based on the biopsy results., A 40-year-old female with no prior history of abnormal Pap smears has a routine Pap smear and HPV DNA test.The test reveals low-risk HPV DNA.The physician counsels the patient regarding the low risk and recommends repeat testing in one year.

* Patient demographics.* Date and type of specimen collection (vaginal).* HPV testing method used.* Specific HPV types detected (if available).* Date of test result.* Physician's interpretation of the results.* Patient education and counseling provided.* Plan for follow-up care (including frequency and type of testing).

** This code should only be used when the DNA test is positive for low-risk HPV types.High-risk HPV types should be coded differently (R87.810 or R87.811).

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.